Mallinckrodt plc (MNK): The stock had negative money flow to the tune of ($2.01 million) on Monday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $4.79 million, whereas, the outflow of money on downticks was $6.8 million and the ratio between the two was 0.7. The block trade had a negative net money flow of ($1.79 million). On the other hand, downticks amounted to $1.79 million of the traded value, which shows distribution in the stock by traders. Mallinckrodt plc (MNK) closed with marginal gains of 6 cents to end the day at $79.76, an increase of 0.08% over the previous days close. The stock recorded -0.29% for the week.
Mallinckrodt Public Limited Company has dropped 0.3% in the last five trading days, however, the shares have posted positive gains of 27.7% in the last 4 weeks. Mallinckrodt Public Limited Company is up 33.5% in the last 3-month period. Year-to-Date the stock performance stands at 6.86%.
Mallinckrodt plc (NYSE:MNK): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.54 and $78.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $79.75, notching a gain of 0.06% for the day. The total traded volume was 1,378,639 . The stock had closed at $79.70 on the previous day.
In a related news, Harbaugh Matthew K, CFO of Mallinckrodt Plc, executed a transaction worth $29,685 on May 10, 2016. A total of 500 shares were purchased at an average price of $59.37. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.